Lexicon Pharmaceuticals (LXRX) Cash from Operations (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly Cash from Operations of 14730000.0 for Q1 2026, up 66.35% year-over-year from 8854666.47 in Q1 2025, and up 14.52% quarter-over-quarter from 17233000.0 in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Cash from Operations (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Cash from Operations for 17 consecutive years, with 14730000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 66.35% year-over-year to 14730000.0; the TTM figure through Mar 2026 stood at 38803000.0 (up 76.82% YoY), while the FY2025 annual figure was 67851000.0, up 62.05% from the prior year.
- Cash from Operations rose to 14730000.0 in Q1 2026 per LXRX's latest filing, from 17233000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 16993000.0 in Q2 2025 and bottomed at 55130000.0 in Q1 2024.
- Historically, Cash from Operations has averaged 30124058.82 across 5 years, with a median of 24422000.0 in 2022.
- Annual changes were most pronounced in 2023 — Cash from Operations slumped 134.35% — and 2025, when it soared 135.01%.
- Lexicon Pharmaceuticals' Cash from Operations stood at 21569000.0 in 2022, then sank by 134.35% to 50548000.0 in 2023, then soared by 57.48% to 21491000.0 in 2024, then grew by 19.81% to 17233000.0 in 2025, then rose by 14.52% to 14730000.0 in 2026.
- Business Quant data shows LXRX's Cash from Operations at 14730000.0 in Q1 2026, 17233000.0 in Q4 2025, and 23833000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Lexicon Pharmaceuticals | 1.04 Bn | 846.13 Mn | 653,000.00 | -9.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.19 Mn |
| Jun 30, 2026 | -9.19 Mn |
| Mar 31, 2026 | -14.73 Mn |
| Mar 31, 2026 | -14.73 Mn |
| Dec 31, 2025 | -17.23 Mn |
| Dec 31, 2025 | -17.23 Mn |
| Sep 30, 2025 | -23.83 Mn |
| Sep 30, 2025 | -23.83 Mn |
| Jun 30, 2025 | 16.99 Mn |
| Jun 30, 2025 | 16.99 Mn |
| Mar 31, 2025 | -43.78 Mn |
| Mar 31, 2025 | -43.78 Mn |
| Dec 31, 2024 | -21.49 Mn |
| Dec 31, 2024 | -21.49 Mn |
| Sep 30, 2024 | -53.62 Mn |
| Sep 30, 2024 | -53.62 Mn |
| Jun 30, 2024 | -48.54 Mn |
| Jun 30, 2024 | -48.54 Mn |
| Mar 31, 2024 | -55.13 Mn |
| Mar 31, 2024 | -55.13 Mn |